Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea

Environmental Toxicology and Pharmacology

Volumn 27, Issue 1, 2009, Pages 26-29

  Maluf, Sharbel ^a   Prá, Daniel ^b   Friedrisch, João R ^a   Bittar, Christina ^a   da Silva, Maria A Lima ^a   Henriques, João A ^b   Silla, Lucia ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Genetic instability; Hydroxyurea; Micronuclei test; Mutagenicity; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MICRONUCLEUS TEST; MUTAGENICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SICKLE CELL ANEMIA; TREATMENT DURATION;

EID: 57149147121     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2008.08.004     Document Type: Article

References (33)

1. Aliverti V., Bonanomi L., and Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch. Toxicol. Suppl. 4 (1980) 239-247
2. Anderson D., Yardley-Jones A., Vives-Bauza C., Chua-Anusorn W., Cole C., and Webb J. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay. Teratog. Carcinog. Mutagen 20 (2000) 251-264
3. Atweh G.F., and Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin. Hematol. 38 (2001) 367-373
4. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br. J. Haematol. 138 (2007) 291-304
5. Brawley O.W., Cornelius L.J., Edwards L.R., Gamble V.N., Green B.L., Inturrisi C., James A.H., Laraque D., Mendez M., Montoya C.J., Pollock B.H., Robinson L., Scholnik A.P., and Schori M. National Institutes of Health Consensus Development Conference Statement: hydroxyurea treatment for sickle cell disease. Ann. Intern. Med. 148 (2008) 932-938
6. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., McMahon R.P., and Bonds D.R. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med. 332 (1995) 1317-1322
7. de Lima P.D., Cardoso P.C., Khayat A.S., de O. Bahia M., and Burbano R.R. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Genet. Mol. Res. 2 (2003) 328-333
8. Fenech M., and Morley A.A. Measurement of micronuclei in lymphocytes. Mutat. Res. 147 (1985) 29-36
9. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat. Res. 285 (1993) 35-44
10. Fenech M. The advantages and disadvantages of the cytokinesis-block micronucleus method. Mutat. Res. 392 (1997) 11-18
11. Fenech M., and Crott J.W. Micronuclei, nucleoplasmic bridges and nuclear buds induced in folic acid deficient human lymphocytes-evidence for breakage-fusion-bridge cycles in the cytokinesis-block micronucleus assay. Mutat. Res. 504 (2002) 131-136
12. Ferster A., Tahriri P., Vermylen C., Sturbois G., Corazza F., Fondu P., Devalck C., Dresse M.F., Feremans W., Hunninck K., Toppet M., Philippet P., Van Geet C., and Sariban E. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97 (2001) 3628-3632
13. Friedrisch J.R., Pra D., Maluf S.W., Bittar C.M., Mergener M., Pollo T., Kayser M., da Silva M.A., Henriques J.A., and da Rocha Silla L.M. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat. Res. 649 (2008) 213-220
14. Gebhart E. Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing. Hum. Genet. 58 (1981) 235-254
15. Griffith K.M. Hydroxyurea (Nsc-32065): results of a phase I study. Cancer Chemother. Rep. 40 (1964) 33-36
16. Hanft V.N., Fruchtman S.R., Pickens C.V., Rosse W.F., Howard T.A., and Ware R.E. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95 (2000) 3589-3593
17. Khayat A.S., Guimaraes A.C., Cardoso P.C., de Lima P.D.L., de M., Bahia O., Antunes L.M.G., and Burbano R.R. Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease. Genet. Mol. Biol. 27 (2004) 115-117
18. Khayat A.S., Antunes L.M., Guimaraes A.C., de M., Bahia O., Lemos J.A., Cabral I.R., Lima P.D., Amorim M.I., Cardoso P.C., and Smith M.A. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin. Exp. Med. 6 (2006) 33-37
19. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., Vichinsky E., Redding-Lallinger R., Gee B., Platt O.S., and Ware R.E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 94 (1999) 1550-1554
20. Koren A., Segal-Kupershmit D., Zalman L., Levin C., Abu Hana M., Palmor H., Luder A., and Attias D. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr. Hematol. Oncol. 16 (1999) 221-232
21. Kumar S., and Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 157 (2005) 175
22. Le Fevre A.-C., Boitier E., Marchandeau J.-P., Sarasin A., and Thybaud V. Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat. Res. Fundam. Mol. Mech. Mutagen 619 (2007) 16-29
23. Li J.C., and Kaminskas E. Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res. 47 (1987) 2755-2758
24. Loukopoulos D., Voskaridou E., Stamoulakatou A., Papassotiriou Y., Kalotychou V., Loutradi A., Cozma G., Tsiarta H., and Pavlides N. Hydroxyurea therapy in thalassemia. Ann. NY Acad. Sci. 850 (1998) 120-128
25. Mancuso A., Maggio A., Renda D., Di Marzo R., and Rigano P. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br. J. Haematol. 133 (2006) 105-106
26. Murphy M.L., and Chaube S. Preliminary survey of hydroxyurea (Nsc-32065) as a teratogen. Cancer Chemother. Rep. 40 (1964) 1-7
27. Ohene-Frempong K., and Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next?. Semin. Hematol. 34 (1997) 30-41
28. Oppenheim J.J., and Fishbein W.N. Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Res. 25 (1965) 980-985
29. Przybyszewski W.M., and Kasperczyk J. Radical mechanism of hydroxyurea side toxicity. Postepy Hig. Med. Dosw. (Online) 60 (2006) 516-526
30. Rogers Z.R. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin. Hematol. 34 (1997) 42-47
31. Steinberg M.H. Management of sickle cell disease. N. Engl. J. Med. 340 (1999) 1021-1030
32. Steinberg M.H., Barton F., Castro O., Pegelow C.H., Ballas S.K., Kutlar A., Orringer E., Bellevue R., Olivieri N., Eckman J., Varma M., Ramirez G., Adler B., Smith W., Carlos T., Ataga K., DeCastro L., Bigelow C., Saunthararajah Y., Telfer M., Vichinsky E., Claster S., Shurin S., Bridges K., Waclawiw M., Bonds D., and Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 2003 (2003) 1645-1651
33. Ziegler-Skylakakis K., Schwarz L.R., and Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat. Res. 152 (1985) 225-231